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Tumor	 necrosis	 factor	 α 	 (TNFα)	 is	 a	 proinflammatory	 cytokine,	 and	
elevated	levels	of	TNFα 	in	serum	are	associated	with	various	autoimmune	
diseases,	including	rheumatoid	arthritis	(RA),	ankylosing	spondylitis	(AS),	
Crohn’s	 disease	 (CD),	 psoriasis	 and	 systemic	 lupus	 erythaematosus.	
TNFα  performs	 its	 pleiotropic	 functions	 by	 binding	 to	 two	 structurally	
distinct	 transmembrane	 receptors,	 TNF	 receptor	 (TNFR)	 1	 and	 TNFR2.	
Antibody-based	therapeutic	strategies	that	block	excessive	TNFα 	signaling	
have	been	shown	to	be	effective	in	suppressing	such	harmful	inflammatory	
conditions.	 Golimumab	 (Simponi®)	 is	 an	 FDA-approved	 fully	 human	
monoclonal	 antibody	 targeting	 TNFα 	 that	 has	 been	 widely	 used	 for	 the	
treatment	 of	RA,	AS	 and	CD.	However,	 the	 structural	 basis	underlying	 the	
inhibitory	action	of	golimumab	remains	unclear.	Here,	we	report	the	crystal	
structure	 of	 the	 Fv	 fragment	 of	 golimumab	 in	 complex	 with	 TNFα 	 at	 a	
resolution	of	2.73	Å.	The	resolved	structure	reveals	that	golimumab	binds	
to	 a	 distinct	 epitope	 on	 TNFα	 that	 does	 not	 overlap	 with	 the	 binding	
residues	 of	 TNFR2.	 Golimumab	 exerts	 its	 inhibitory	 effect	 by	 preventing	
binding	of	TNFR1	and	TNFR2	to	TNFα	by	steric	hindrance.	Golimumab	does	
not	 induce	 conformational	 changes	 in	 TNFα 	 that	 could	 affect	 receptor	
binding.	This	mode	of	action	is	specific	to	golimumab	among	the	four	anti-
TNFα 	therapeutic	antibodies	currently	approved	for	clinical	use.		
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A	 50-75-word	 statement,	 written	 for	 a	 broader	 audience,	 outlining	 the	




Tumor	necrosis	 factor	α	(TNFα)	 is	a	pleiotropic	cytokine	 involved	 in	regulating	diverse	 bodily	 functions,	 including	 cell	 growth	 modulation,	 inflammation,	carcinogenesis,	 viral	 replication,	 septic	 shock	 and	 autoimmunity.1	 TNFα	performs	 its	 functions	 by	 binding	 to	 two	 structurally	 distinct	 membrane	receptors,	TNFR1	 (also	 known	 as	p55)	 and	TNFR2	 (p75).2	TNFα	 signaling	 via	TNFR1	 is	 predominantly	 associated	 with	 inflammation	 and	 apoptosis.	 In	contrast,	TNFR2	is	mainly	implicated	in	regulation	of	T-cell	migration	and	tissue	regeneration.	 Because	 of	 its	 pleiotropic	 actions,	 the	 biosynthesis	 of	 TNFα	 is	under	 strict	control	 of	multiple	 and	 complex	 regulatory	mechanisms,	 including	gene	transcription,	mRNA	turnover,	translation	and	intracellular	signaling	of	the	protein.	Dysregulation	of	 TNFα	production	 can	 result	 in	 elevated	 serum	TNFα	levels	and	the	development	of	various	 inflammatory	and	autoimmune	diseases,	such	as	 rheumatoid	arthritis	 (RA),	ankylosing	 spondylitis	 (AS),	Crohn’s	disease	(CD),	psoriasis	and	systemic	lupus	erythaematosus.3	
Recently,	therapeutic	strategies	that	block	excessive	TNFα	signaling	have	emerged	 to	 suppress	 these	 harmful	 inflammatory	 conditions.	 To	 date,	 the	following	 five	 molecules	 have	 been	 approved	 by	 the	 FDA	 as	 effective	 TNFα	inhibitors	 for	 clinical	 use	 and	 led	 to	 significant	 advances	 in	 autoimmune	inflammatory	 disease	 therapy:	 infliximab	 (Remicade®;	 humanized	 chimeric	monoclonal	 antibody	 (mAb)	 of	 the	 isotype	 IgG1),	 adalimumab	 (Humira®;	 fully	human	 mAb	 of	 the	 IgG1/κ	 isotype),	 certolizumab	 pegol	 (Cimzia®;	 PEGylated	humanized	 Fab	 fragment),	 golimumab	 (Simponi®;	 fully	 human	 mAb	 of	 the	IgG1/κ	isotype)	and	etanercept	(Enbrel®;	Fc-TNFR2	fusion	protein).4	These	new	
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biologic	 agents	 have	 changed	 the	 paradigm	 of	 RA	 treatment,	 leading	 to	improvements	 in	 controlling	 the	 signs	 and	 symptoms	 of	 RA	 refractory	 to	classical	 low-molecular-weight	 drugs	 such	 as	 methotrexate	 (MTX),	 and	 in	slowing	 joint	 destruction.5	 The	 concentration	 of	 golimumab	 necessary	 to	neutralize	 TNFα-induced	 E-selectin	 expression	 on	 human	 endothelial	 cells	 by	50%	 is	 reported	 to	 be	 less	 than	 those	 for	 infliximab	 and	adalimumab.6	Nevertheless,	patients	 currently	 treated	with	an	anti-TNFα	agent	may	remain	refractory	or	become	nonresponsive	to	the	treatment.7	In	addition,	a	sizable	 proportion	 of	 patients	 experience	 adverse	 events,	 such	 as	 hepatitis	 B	infection	and	tuberculosis.8	Once	a	primary	TNFα	 inhibitor	fails,	a	patient	must	switch	to	another	anti-TNFα	agent	that	has	a	complementary	mode	of	action	or	differs	in	its	capacity	to	induce	immunogenicity.9	




The	 soluble	 forms	of	 the	human	TNFα	and	 the	Fv	 fragment	 of	 the	 golimumab,	both	 of	 which	 contain	 intrachain	 disulfide	 bonds,	 were	 produced	 by	 a	 Gram-positive	bacterial	 secretory	 expression.	For	 production	of	 the	 Fv	 fragment,	 the	“iRAT	 (intervening	 removable	 affinity	 tag)”	 system	 was	 used	 to	 ensure	stoichiometric	 expression	 of	 heavy	 (VH)-	and	 light	 (VL)-chain	 variable	 domains	followed	 by	 correct	 folding	 and	 assembly.13	 By	 employing	 these	 recombinant	proteins,	 the	 TNFα:golimumab	 Fv	 complex	 (subsequently	 referred	 to	 as	 the	TNFα:golimumab	complex)	was	prepared.	Analytical	gel	filtration	confirmed	that	the	 stoichiometrically	 saturated	 1:3	 TNFα	 homotrimer:golimumab	 complex	(approximately	 126	kDa)	 exists	 as	 a	monomer	 in	 solution	 (Supplementary	 Fig.	S1A,	 S1B).	The	 crystals	of	TNFα:golimumab	 complex	 (Supplementary	Fig.	 S1C)	appeared	 in	 the	P21	space	group	and	diffracted	X-rays	 to	2.73	Å	 (Table	1).	The	structure	was	 resolved	 by	molecular	 replacement	 using	 the	 existing	 TNFα	apo	structure	 (PDB	code:	1A8M)14	and	pembrolizumab	Fv	 (PDB	code:	5B8C).15	The	asymmetric	unit	contained	two	copies	of	the	TNFα	homotrimer	and	six	copies	of	the	 golimumab	 Fv,	 thus	providing	 six	 copies	 of	 the	 TNFα:golimumab	 interface	related	by	non-crystallographic	symmetry	(NCS).	The	side-chain	electron	density	was	 sufficiently	 resolved	 throughout	 the	 TNFα:golimumab	 interface	(Supplementary	Fig.	S1D	and	S1E).	
The	 three-dimensional	 arrangement	 of	 the	 biologically	 relevant	TNFα:golimumab	 complex	has	an	overall	 shape	 that	 resembles	a	bell,	with	 the	
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TNFα	trimer	and	the	three	Fv	fragments	sitting	at	the	shoulder	of	the	bell	(Fig.	1A,	 left).	In	this	binding	orientation,	the	golimumab	would	point	away	from	the	membrane	 in	 the	membrane-bound	 form	of	TNFα,	with	 the	membrane	 located	below	the	TNFα	molecule	in	Fig.	1A	(left).	Therefore,	golimumab	not	only	binds	the	 soluble	 form	 of	 TNFα	 but	 also	may,	 in	 principle,	 be	 able	 to	 bind	 to	 TNFα	before	 it	 is	 released	 from	 its	membrane-bound	precursor.	 This	 structure-based	assumption	is	in	line	with	a	pervious	pharmacological	data	that	golimumab	IgG	bind	 to	membrane-bound	TNFα	with	an	apparent	dissociation	constant	 (KD)	of	1890	pM.6	When	viewed	along	 the	 intrinsic	3-fold	axis	of	 the	TNFα	 trimer,	 the	biologically	 relevant	 complex	 resembles	 a	 three-bladed	 propeller,	 with	 each	TNFα:Fv	protomer	forming	one	blade	(Fig.	1A,	right).	The	epitope	important	for	binding	 and	 specificity	 is	 located	 within	 a	 single	 TNFα	 protomer,	 and	 the	 Fv	fragments	do	not	bridge	protomers	in	the	trimer.	The	pseudo	2-fold	axis	of	the	Fv	fragments	relating	the	VH	and	VL	domains	is	not	perpendicular	to	the	3-fold	axis,	and	 the	 Fv	 fragments	 are	 tilted	 ~45°	 out	 of	 the	 plane	 (Fig.	 1A).	 Structural	alignment	 of	 the	 TNFα:TNFR2	 complex16	 with	 the	 TNFα:golimumab	 complex	shows	no	major	perturbations	in	the	TNFR2	binding	sites	except	for	the	DE	loop	of	 TNFα	 (Fig.	 1B).	 The	 aberrant	 positioning	 of	 the	 DE	 loop	 in	 the	TNFα:golimumab	complex	might	be	caused	by	a	crystallization	artifact	related	to	the	packing	contacts	between	the	peripheral	regions	of	molecules	rather	than	a	biologically	relevant	conformational	change	caused	by	binding	of	golimumab.	In	the	 crystals,	 the	 DE	 loop	 of	one	 TNFα	molecule	 interacts	with	 its	neighboring	TNFα	 molecule	 via	 hydrogen	 bonds	 (Supplementary	 Fig.	 S2).	 Furthermore,	 it	cannot	be	assumed	that	 the	DE	 loop,	which	 is	situated	distal	 to	 the	golimumab	
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epitope,	 specifically	 undergoes	 allosteric	 conformational	 changes	 even	 though	proximal	regions	exhibit	no	apparent	shift	upon	golimumab	binding.	
Because	 of	 the	 high	 affinity	 of	 golimumab	 for	TNFα,	 we	 assume	 that	 a	stoichiometrically	saturated	1:3	TNFα	homotrimer:golimumab	complex	could	be	formed	in	vivo,	although	molecular	populations	of	the	1:3	complex	might	not	be	dominant,	 which	 is	 similar	 to	 the	 cases	 of	 higher-order	 structures	 of	TNFα:adalimumab	 and	 TNFα:infliximab	 complexes	 as	 recently	 shown	 by	negative	 stain	 TEM	 and	 cryo-EM	 techniques.17	 However,	 formation	 of	 the	 1:3	complexes	is	not	be	necessary	for	inhibition	of	signaling	via	TNFRs	because	this	type	 of	 signaling	 requires	 multiple	 intact	 TNFR-binding	 sites	 on	 the	 TNFα	homotrimer,	 as	 demonstrated	 by	 inhibition	 of	 signaling	when	TNFα	exchanges	protomers	with	dominant-negative	TNFα	variants.18	
	
Golimumab	epitope	
To	 establish	 the	 residues	 that	 fall	within	 the	 golimumab	 epitope	 on	 TNFα,	 we	analysed	 the	 interfaces	 of	 the	 TNFα:golimumab	 complex	 via	 PISA.19	 All	 NCS	copies	share	the	same	pattern	of	intermolecular	contacts,	which	involve	13	TNFα	residues	and	bury	surface	areas	of	905	Å2	and	997	Å2	on	TNFα	and	golimumab,	respectively	 (Fig.	 2A).	 These	are	 in	 the	 typical	 range	 of	 the	 interaction	 surface	between	 antibodies	 and	 protein	 antigens.20	 The	 golimumab	 heavy	 chain	contributed	781	Å2	of	the	buried	solvent-accessible	area,	whereas	the	light	chain	contributed	 216	 Å2.	 The	 golimumab	 is	 bound	 to	 a	 discontinuous	 epitope	composed	of	residues	in	the	AA’	loop	(Gly24T),	C	strand	(Lys65T,	Gln67T),	CD	loop	
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(Ser71T),	 EF	 loop	 (Glu104T,	 Thr105T,	 Pro106T,	 Glu107T,	 Gly108T,	 Ala111T)	 and	GH	loop	(Arg138T,	Asp140T,	Tyr141T)	of	TNFα	(hereafter,	residues	of	the	TNFα	and	golimumab	Fv	heavy	chain	and	light	chain	are	designated	by	the	superscript	chain	 identifiers	 T,	 H,	 and	 L,	 respectively).	 Over	 18	 pairs	 of	 interactions	 are	observed,	including	11	direct	hydrogen	bonds	between	residues,	at	least	3	water-mediated	 hydrogen	 bonds,	 3	 salt	 bridges,	 1	 aromatic	 side-chain	 contact	 and	hydrophobic	 interactions,	which	 indicate	 a	 stable	 interaction	network	between	the	 two	 proteins	 and	may	 explain	 their	 high	 binding	 affinity	 (KD=18	pM	when	measured	using	soluble	 form	of	TNFα	and	golimumab	IgG).6	The	recognition	of	the	 epitope	 is	 mainly	 achieved	 by	 the	 complementarity-determining	 region	(CDR)	loops	of	the	heavy	chain.	Most	prominently,	residues	located	in	the	EF	loop	of	TNFα	provide	a	key	component	of	the	interactions,	mainly	through	hydrogen	bonds	 and	 salt	 bridges	 to	 the	CDR-H1	 (Ser31H)	 and	CDR-H3	 (Arg98H,	Arg100H	and	Tyr111H)	of	golimumab	(Fig.	2B	and	Supplementary	Fig.	S2).	Arg100H	makes	the	 largest	 contribution	 to	 the	 TNFα:golimumab	 interaction	 and	 presents	 a	binding	 free	 energy	 of	 -7.7	 kcal/mol	 as	 calculated	 with	 ANCHOR.21	 From	 the	golimumab	 light	 chain,	 only	 two	 residues,	 Tyr30L	 and	 Tyr32L	 in	 CDR-L1,	 are	involved	 in	 the	 interaction	 with	 Gly24T	 (AA’	 loop)	 and	 Asp140T	 (GH	 loop),	respectively.	
Notably,	the	TNFα	residues	interacting	with	golimumab	CDRs	are	distinct	from	those	that	engaged	TNFR2	(Fig.	2A	and	Supplementary	Fig.	S3).	A	previous	crystallographic	 study	 of	 the	TNFα:TNFR2	 complex	 (PDB	 code:	 3ALQ)	 showed	that	the	cysteine-rich	domain	2	(CRD2)	and	CRD3	of	TNFR2	have	contacts	with	residues	 in	 the	AA’	 loop	 (Gln21T,	 Glu23T,	 Arg31T,	 Arg32T,	 Ala33T)	 and	GH	 loop	
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(Asp143T)	of	one	TNFα	protomer,	and	the	DE	loop	(Ser86T,	Tyr87T,	Pro90T)	of	a	neighbouring	 protomer16.	 None	 of	 these	 residues	 participates	 in	 polar	interactions	 within	 the	 TNFα:golimumab	 complex;	 hence,	 direct	 competition	does	not	occur	between	 the	binding	 residues	of	 golimumab	and	TNFR2,	which	represents	an	 idiosyncratic	antagonistic	 feature	exhibited	by	golimumab	that	 is	not	shared	with	the	other	three	anti-TNFα	antibodies.	The	latter	three	antibody	epitopes	 have	 overlapping	 portions	 with	 the	 binding	 footprint	 of	 TNFR2,	including	buried	 solvent-accessible	 surface	 areas	 of	 26.1	 Å2	 for	 infliximab	 (Fig.	2C),	211.7	Å2	for	adalimumab	(Fig.	2D)	and	224.9	Å2	for	certolizumab	(Fig.	2E).	
	
TNFR	steric	competition	properties	of	golimumab	
Because	 golimumab	 inhibition	 of	 TNFR	 binding	 could	 not	 arise	 from	 direct	competition	 for	 receptor-binding	 residues	 on	 TNFα	 and/or	 potential	golimumab-induced	 conformational	 changes	 in	 TNFα,	 steric	 clashes	 caused	 by	physical	overlap	between	the	bound	golimumab	and	TNFRs	could	be	substantial	and	critical	to	golimumab’s	 inhibitory	activity.	To	gain	quantitative	 insights	 into	the	 effect	 of	 inhibitor	 overlap	 on	 blocking	 TNFα	 interactions	 with	 TNFRs,	 we	calculated	 the	 theoretical	 volumes	 of	 atomic	 overlap	 between	 golimumab	 and	TNFR2.	 First,	 we	 performed	 a	 structural	 alignment	 of	 the	 TNFα:golimumab	complex	 with	 the	 TNFα:TNFR2	 complex.	 We	 then	 calculated	 the	 volumes	 of	atomic	 overlap	 between	 the	 superimposed	 golimumab	 and	 TNFR2	 (Fig.	 3).	Similar	analyses	were	also	performed	for	infliximab	(Supplementary	Fig.	S4A	and	S4B),	 adalimumab	 (Supplementary	 Fig.	 S4C	 and	 S4D)	 and	 certolizumab	
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(Supplementary	Fig.	S4E	and	S4F).	Surprisingly,	golimumab	exhibits	a	volume	of	steric	conflict	with	TNFR2	(30	Å3)	that	is	an	order	of	magnitude	smaller	than	that	of	 the	 other	 three	 anti-TNFα	 antibodies	 (infliximab	 versus	 TNFR2=1,800	 Å3;	adalimumab	versus	TNFR2=2,090	Å3;	and	certolizumab	versus	TNFR2=820	Å3).		
Furthermore,	 the	 atomic	 overlapping	 volumes	 between	 anti-TNFα	antibodies	 and	 TNFR1	 were	 calculated.	 Because	 the	 structure	 of	 the	TNFα:TNFR1	 complex	 has	 not	 been	 determined,	 we	 used	 the	 structure	 of	 the	lymphotoxin-α	 (TNFβ):TNFR1	 complex	 (PDB	 code:	 1TNR)22	 as	 a	 template	 to	generate	a	model	of	TNFα:TNFR1	complex,	which	was	then	superimposed	with	the	 TNFα:antibody	 complexes.	 This	 analysis	 revealed	 that	 significant	 steric	clashes	occur	between	 golimumab	 and	TNFR1	 (360	Å3)	 (Fig.	 4),	 although	 they	are	smaller	than	those	of	the	other	three	anti-TNFα	antibodies	(infliximab	versus	TNFR1=1,820	Å3;	adalimumab	versus	TNFR1=2,110	Å3;	and	certolizumab	versus	TNFR1=530	Å3)	(Supplementary	Fig.	S5).	This	steric	conflict	between	golimumab	and	TNFR1	underlies,	 in	part,	 the	therapeutic	efficacy	of	golimumab,	which	has	strong	inhibitiory	effects	on	TNFα-binding	to	TNFR1	and	presents	an	IC50	of	3.9	ng/mL	as	previously	described.6		
Interestingly,	 golimumab’s	 physical	 overlapping	 volumes	 with	 the	 two	TNFRs	 are	 drastically	 different.	 Such	 a	 disparity	 is	not	 observed	 for	 the	 other	three	 anti-TNFα	 antibodies.	 However,	 given	 that	 even	 a	 small	 overlapping	volume	between	 the	 receptor	and	 the	antibody	can	cause	 steric	 repulsion,	 it	 is	clear	that	golimumab	exhibits	competitive	inhibitory	action	against	both	TNFR1	and	 TNFR2.	 Previous	 functional	 analyses	 of	 TNFRs	 have	 demonstrated	 the	predominant	 role	 of	 TNFR1	 in	 the	 pathogenesis	 and	 exacerbation	 of	
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inflammation.23,	 24	 Moreover,	 TNFR2	 has	 been	 shown	 to	 be	 crucial	 for	 the	proliferation,	activation	and	antigen	presentation	of	T-cells,	which	are	essential	in	cell-mediated	 immune	 responses	against	 bacteria	 and	 viruses.25	Blocking	 all	effect	of	TNFRs	signaling	can	therefore	be	counter-productive.	Clinical	trials	have	assessed	the	side	effects	of	golimumab	treatment	and	reported	an	increased	risk	of	 infections,	 reactivation	 of	 tuberculosis,	 invasive	 fungal	 infections,	 and	 other	opportunistic	 infections.26,	27	These	adverse	 drug	 reactions	 can	be	 explained	 in	part	by	our	 finding	 that	golimumab	sterically	hinders	TNFR2	as	well	as	TNFR1	from	associating	with	TNFα	(Figs.	3	and	4).	








The	cloned	Homo	sapiens	TNFα	sequence	contains	residues	77	to	233	of	the	233	total	residues	(UniProt	accession	number:	P01375),	with	the	FLAG-tagged	at	the	N-terminus	 underlined	 and	 additional	 C-terminal	 residues	 retained	 after	restriction	 site	 cloning	 or	 tobacco	 etch	 virus	 (TEV)	 cleavage	 shown	 in	 italics	(refer	to	the	following	section	for	cloning	details):	
DYKDDDDKVRSSSRTPSDKPVAHVVANPQAEGQLQWLNRRANALLANGVELRDNQLVVPSEGLYLIYSQVLFKGQGCPSTHVLLTHTISRIAVSYQTKVNLLSAIKSPCQRETPEGAEAKPWYEPIYLGGVFQLEKGDRLSAEINRPDYLDFAESGQVYFGIIALTSENLYFQ	














The	protein	complex	was	prepared	by	incubating	TNFα	with	golimumab	Fv	at	a	molar	 ratio	 of	 1:6	 for	 1	 h	 on	 ice.	 The	 complex	was	 subjected	 to	 size	 exclusion	chromatography	(Superdex	200	10/300	column,	GE	Healthcare).	Peak	 fractions	containing	 the	 TNFα:golimumab	 Fv	 complex	 were	 concentrated	 to	approximately	10	mg/mL	by	ultrafiltration	(Millipore,	MWCO	50	kDa)	and	used	for	crystallization	 experiments.	The	 crystals	 of	 the	 complex	used	 for	 structural	determination	were	 grown	 at	 20°C	 by	 hanging	 drop	 vapor	 diffusion.	 A	 400	µL	reservoir	 containing	 0.1	 M	 sodium	 acetate	 (pH	 4.6)	 and	 1.4	 M	 NaCl	 was	equilibrated	 against	 a	 2	 µL	 drop	 containing	 a	 1:1	mixture	 of	 the	 complex	 and	reservoir	solution.	After	14-21	days	of	growth,	the	crystals	were	cryo-protected	in	 25%	 ethylene	 glycol	 in	 the	 mother	 liquor	 and	 then	 flash-frozen	 in	 liquid	nitrogen.	
	
Data	collection,	structure	determination	and	analysis	
The	diffraction	data	were	 collected	 at	 100	K	 at	 the	 SPring-8	beamline	BL41XU	(Japan)	using	a	PILATUS3	6M	detector.	The	data	were	then	integrated	and	scaled	using	XDS.28	The	structure	of	the	TNFα:golimumab	Fv	complex	was	determined	by	 molecular	 replacement	 with	 the	 program	 MR-PHASER29	 using	 the	 atomic	coordinates	 of	 the	 human	 TNFα	 apo	 structure	 (PDB	 code:	 1A8M)	 and	 the	pembrolizumab	 Fv	 (PDB	 code:	 5B8C)	 as	 the	 search	 models.	 The	 model	 was	further	rebuilt	 in	COOT30	and	refined	with	phenix.refine31	(Table	1).	In	the	final	Ramachandran	plot,	95.6%	and	4.1%	of	residues	were	in	the	favored	and	allowed	
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regions,	 respectively.	 The	 refined	 structures	 were	 visualized	 with	 PyMOL	(http://www.pymol.org/).	The	PISA	server19	was	used	to	identify	protein-protein	interactions	and	estimate	the	solvent-accessible	surface	area.	The	model	complex	of	 TNFα:TNFR1	was	 constructed	 based	 on	 the	 structural	 alignment	 of	 the	 LTα	(TNFβ):TNFR1	complex	(PDB	code:	1TNR)22	and	the	TNFα:TNFR2	complex	(PDB	code:	3ALQ)16	using	a	superimposing	program	in	UCSF	Chimera.32	The	volumes	of	physical	overlap	of	 each	anti-TNFα	antibody	with	TNFRs	were	 calculated	by	the	volumes	tool	in	Chimera.	
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Additional	Information	




X-ray	data	collection	 		 Source,	wavelength	 SPring-8	BL41XU,	1.00000	Å		 Resolution	(Å)a	 46.25-2.73	(2.80-2.73)		 Space	group	 P21		 Unit	cell	parameter	(Å,	°)	 a=133.6,	b=85.3,	c=136.0,	α=90.0,	β=101.6,	γ=90.0		 Unique	reflectionsa	 77915	(5439)		 Redundancya	 3.4	(3.5)		 Completenessa	 97.1	(92.8)		 Rmerge	(%)a	 10.7	(98.8)		 CC1/2	(%)a	 99.3	(53.9)	
	 <I/σ(I)>a	 9.5	(1.5)		 	 	
Refinement	 		 Resolution	(Å)a	 46.25–2.73	(2.76-2.73)		 Rwork	/Rfree	(%)a,b	 19.0	/	23.4	(35.4	/	39.9)		 R.m.s.	deviations	 		 Bonds	(Å)	 0.003		 Angles	(°)	 0.672		 No.	of	atoms	(average	B-factors	(Å2))	 		 TNFα	 7194	(81.8)		 				golimumab	Fv	 10836	(75.4)		 Water	 86	(59.3)		 	 	





































Supplementary	 Figure	 S1.	 	 Crystallography	 of	 the	 TNFα:golimumab	 Fv	


















Supplementary	 Figure	 S4.	 Competitive	 binding	 between	 FDA-approved	





Supplementary	 Figure	 S5.	 Models	 for	 competitive	 binding	 between	 FDA-
approved	 anti-TNFα 	 mAbs	 and	 TNFR1.	 Structural	 alignment	 of	 TNFα:mAb	complex	and	TNFα:TNFR1	complex	model	reveals	that	the	mAb	light	chain	(red)	and	mAb	 heavy	 chain	 (blue)	 have	 a	 significant	 penetration	 into	 the	 volume	 of	TNFR1	 (light	blue),	which	would	 allow	 the	mAbs	 to	block	TNFR1	binding.	The	aligned	 structures	 are	 rotated	 by	 90°	 around	 the	 horizontal	 axis.	 Infliximab	 is	shown	in	(A)	and	(B);	adalimumab	is	shown	in	(C)	and	(D);	and	certolizumab	is	shown	in	(E)	and	(F).	
	
